For Immediate Release:
NEWTOWN, PA — The Bracken Group (Bracken) is pleased to announce two new Senior Partners have joined the company: Martin Collyer, FCCA, MSc and Ina Margaretha Rijnhout, MSc, expanding the depth and breadth of the company’s consulting team.
Martin Collyer, FFCA, MSc
As a seasoned executive in healthcare operations, finance, patient engagement/retention and strategy, Martin has held various leadership roles, all of which included managing global teams and driving growth across both clinical and commercial operations. His background also includes strategic planning, execution, process optimization, and product design and development, most recently working with Apple and Samsung. His expertise is as broad as it is deep, spanning executive and senior executive roles, including at IQVIA, PRA Health Sciences, Bayer Healthcare, Clario (previously Bioclinica), Hitachi Data, Huntsworth Health, and Wolters Kluwer. Martin holds a Master of Science (MSc) in professional accountancy from the University of London and is a fellow of the Association of Chartered Certified Accountants (ACCA) in the UK.
Ina Rijnhout, MSc
Based in the Netherlands, Ina has held various leadership roles in the fields of clinical drug development, business development, building innovative biotech businesses and driving growth in multiple CROs in Europe. Over the course of her career, Ina has successfully been identifying promising technologies, building start-ups, organizing funding (including European grants), and leading R&D programs from bench to bedside to develop groundbreaking therapies, ultimately negotiating attractive licensing deals to accelerate time to market. She has experience in the field of immunology, allergy, inflammatory diseases (including post-COVID), musculoskeletal diseases, and CNS, including multiple orphan diseases and advanced therapies, such as gene and cell therapies and combined medical devices. At Bracken, Ina Margaretha is supporting clients with building vital scientific and operational teams, clinical development planning and execution and developing long-term alliances, licensing and M&A deals with biopharma partners to create, bring, and deliver innovative treatments to patients.
Colin G. Miller, PhD, FIPEM, CSci, CEO of Bracken, stated, “The Bracken Group continues to attract highly talented and seasoned individuals who collectively allow us to provide our clients the insights and services they require, whether it is a due diligence project, a long-term strategy project or use one or more of our team as a “virtual C-suite”. I am delighted to have Ina and Martin as part of our team and support our growing list of clients from start-ups up to Fortune 500 companies.”
About Bracken
Bracken offers consulting, regulatory, analytics, marketing, and sales enablement solutions for the life sciences and digital health industries. Through highly experienced consultative support, business programs, and data-enabled products, Bracken provides a multidisciplinary approach to exceeding goals for their clients.
Contact us today to learn more about our services and working directly with Bracken’s team of expert consultants. Website: www.thebrackengroup.com.
